Associated equity: Cantargia
Cantargia is a clinical-stage biotechnology company based in Sweden. It is developing two assets against IL1RAP, CAN04 and CAN10. CAN04 is being studied in several solid tumours with a main focus on non-small cell lung cancer (NSCLC) and pancreatic cancer. The most advanced trial is in Phase II.
Cantargia — 8 videos in collection
Cantargia is a clinical-stage biotechnology company based in Sweden, established in 2009 and listed on the Nasdaq Stockholm main market. It is developing two assets against IL1RAP, CAN04 and CAN10. The lead clinical trial is a Phase IIa CANFOUR study with CAN04 in non-small cell lung cancer and pancreatic cancer. Cantargia is also running a Phase I trial in the United States with CAN04 in combination with checkpoint inhibitors in various solid tumours. Another Phase Ib trial is being prepared and will expand the target patient population in pancreatic cancer.
In this video, Göran Forsberg, Cantargia’s chief executive officer, addresses the recent news flow for Novartis, which has announced results from one of its Phase III trials with a potential competitor drug. He then provides an overview of Cantargia’s latest R&D progress and expected rich news flow this year.
Get access to the very latest content matched to your personal investment style.